Auna announces Q3 adjusted EBITDA of PEN231M, a 7% decrease compared to last year.
Q3 Revenue Performance: Auna reported a Q3 revenue of PEN1.12B, reflecting a 1% decrease year-over-year, indicating challenges in financial performance despite operational resilience.
Operational Growth in Peru and Colombia: The company experienced significant growth and profitability in local currency in Peru and Colombia, driven by increased memberships and pricing adjustments, particularly in Oncosalud and Healthcare Services.
Stability in Mexico Operations: Auna's operations in Mexico showed stability amidst recovery from previous challenges, although financial results in this segment were less favorable.
Cost Containment and Efficiency: The company's disciplined cost management and operational efficiency, particularly in its medical talent, contributed to the strong performance in Peru, with an improved Oncology MLR of 49.3%.
Trade with 70% Backtested Accuracy
Analyst Views on AUNA
About AUNA
About the author
Auna Executes Addendum to PPP Agreement with EsSalud
- Project Milestone: Auna's signing of the addendum with EsSalud formally authorizes the construction of the Torre Trecca project, which is expected to commence operations in mid-2028, significantly enhancing healthcare capacity in metropolitan Lima.
- Service Expansion: Torre Trecca will provide approximately 600,000 patient services in its first operational year, with plans for annual increases, aiming to reduce waiting times for over six million insured Peruvians.
- Infrastructure Investment: The project operates under a 20-year concession framework, with Auna's construction capital expenditures reimbursed by EsSalud through progress certificates, ensuring predictable revenue streams and minimizing financial risk.
- Strategic Market Opportunity: Auna's CEO emphasized that this partnership not only expands its market reach in Peru but also enhances the company's competitiveness in the Latin American healthcare sector by delivering high-quality medical services.
Auna S.A. Announces 2025 Financial Results Dates
- Earnings Release Schedule: Auna S.A. is set to report its Fourth Quarter and Full-Year 2025 financial results on March 10, 2026, after market close, which is expected to provide investors with critical performance data to assess the company's future growth potential.
- Conference Call Timing: The company will hold a conference call on March 11, 2026, at 8:00 a.m. ET to provide a detailed interpretation of the financial results and answer investor questions, thereby enhancing transparency and investor confidence.
- Quiet Period Details: Auna will enter a quiet period from February 23 to March 10, 2026, during which no public discussions related to financial performance will occur, ensuring compliance and fairness in information disclosure.
- Company Background: Auna is a leading healthcare services and plan provider in Latin America, focusing on high-complexity diseases, with a network of 31 healthcare facilities and 2,333 beds, serving 1.4 million healthcare plans, showcasing its strong integration capabilities in the Spanish-speaking markets.
Auna S.A. Announces 2025 Financial Results Dates
- Earnings Release Schedule: Auna S.A. will report its Fourth Quarter and Full-Year 2025 financial results after market close on March 10, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: The company plans to hold a conference call on March 11, 2026, at 8:00 a.m. ET to discuss financial results and address investor inquiries, aiming to enhance market confidence.
- Quiet Period Details: Auna's quiet period will run from February 23 to March 10, 2026, indicating the company's cautious approach to information disclosure prior to earnings release to avoid market misinterpretation.
- Company Background: Auna is a leading healthcare services and plan provider in Latin America, operating 31 healthcare network facilities and managing 1.4 million healthcare plans, focusing on high-complexity diseases, showcasing its strong integration capabilities in the Spanish-speaking markets.
EsSalud Receives Construction License for Torre Trecca, Signifying Important Milestone in Auna's Public-Private Partnership with the Organization
Construction License Received: Auna S.A. has received a construction license for Torre Trecca, a high-rise outpatient treatment center in Lima, Peru, which will serve over six million EsSalud-insured Peruvians.
Public-Private Partnership: The project is part of a public-private partnership with EsSalud, initiated in 2010, aimed at modernizing healthcare services in the region.
Expected Impact: Once completed, Torre Trecca is projected to accommodate more than three million visits annually, significantly enhancing healthcare access in Lima.
Forward-Looking Statements: Auna's announcement includes forward-looking statements regarding the project's timeline and capacity, emphasizing potential risks and uncertainties that may affect outcomes.
Honeywell Analyst Adopts Bearish Stance; Check Out Tuesday's Top 4 Downgrades
Analyst Downgrades: JP Morgan's Hanzade Kilickiran downgraded D-MARKET Electronic from Overweight to Neutral, lowering the price target from $4.85 to $3.07, with shares closing at $2.31.
Federal Realty Investment Trust: Barclays analyst Richard Hightower downgraded Federal Realty Investment Trust from Overweight to Equal-Weight, reducing the price target from $113 to $106, while shares closed at $96.00.
Auna SA: JP Morgan's Joseph Giordano downgraded Auna SA from Overweight to Neutral, cutting the price target from $13.5 to $6, with shares closing at $5.00.
Honeywell International Inc: B of A Securities analyst Andrew Obin downgraded Honeywell from Buy to Underperform, slashing the price target from $265 to $205, as shares closed at $196.08.
Alphabet Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Tuesday
Analyst Upgrades and Price Target Increases: HC Wainwright & Co. raised the price target for Zymeworks Inc. from $26 to $32 while maintaining a Buy rating. Jefferies also increased the price target for Legence Corp. from $39 to $49 and upgraded the stock from Hold to Buy.
Analyst Downgrades and Price Target Cuts: BTIG cut the price target for LifeMD Inc. from $18 to $10, while JP Morgan reduced Auna SA's target from $13.5 to $6 and downgraded it from Overweight to Neutral.
Mixed Ratings and Price Adjustments: Canaccord Genuity lowered TELA Bio Inc.'s price target from $7 to $4 but kept a Buy rating, whereas B of A Securities cut Honeywell International Inc.'s target from $265 to $205 and downgraded it from Buy to Underperform.
Other Notable Changes: Loop Capital raised Alphabet Inc.'s price target from $260 to $320 and upgraded it from Hold to Buy, while HC Wainwright & Co. increased HIVE Digital Technologies Ltd.'s target from $8 to $10, maintaining a Buy rating.
Auna Executes Addendum to PPP Agreement with EsSalud
- Project Milestone: Auna's signing of the addendum with EsSalud formally authorizes the construction of the Torre Trecca project, which is expected to commence operations in mid-2028, significantly enhancing healthcare capacity in metropolitan Lima.
- Service Expansion: Torre Trecca will provide approximately 600,000 patient services in its first operational year, with plans for annual increases, aiming to reduce waiting times for over six million insured Peruvians.
- Infrastructure Investment: The project operates under a 20-year concession framework, with Auna's construction capital expenditures reimbursed by EsSalud through progress certificates, ensuring predictable revenue streams and minimizing financial risk.
- Strategic Market Opportunity: Auna's CEO emphasized that this partnership not only expands its market reach in Peru but also enhances the company's competitiveness in the Latin American healthcare sector by delivering high-quality medical services.
Auna S.A. Announces 2025 Financial Results Dates
- Earnings Release Schedule: Auna S.A. is set to report its Fourth Quarter and Full-Year 2025 financial results on March 10, 2026, after market close, which is expected to provide investors with critical performance data to assess the company's future growth potential.
- Conference Call Timing: The company will hold a conference call on March 11, 2026, at 8:00 a.m. ET to provide a detailed interpretation of the financial results and answer investor questions, thereby enhancing transparency and investor confidence.
- Quiet Period Details: Auna will enter a quiet period from February 23 to March 10, 2026, during which no public discussions related to financial performance will occur, ensuring compliance and fairness in information disclosure.
- Company Background: Auna is a leading healthcare services and plan provider in Latin America, focusing on high-complexity diseases, with a network of 31 healthcare facilities and 2,333 beds, serving 1.4 million healthcare plans, showcasing its strong integration capabilities in the Spanish-speaking markets.
Auna S.A. Announces 2025 Financial Results Dates
- Earnings Release Schedule: Auna S.A. will report its Fourth Quarter and Full-Year 2025 financial results after market close on March 10, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: The company plans to hold a conference call on March 11, 2026, at 8:00 a.m. ET to discuss financial results and address investor inquiries, aiming to enhance market confidence.
- Quiet Period Details: Auna's quiet period will run from February 23 to March 10, 2026, indicating the company's cautious approach to information disclosure prior to earnings release to avoid market misinterpretation.
- Company Background: Auna is a leading healthcare services and plan provider in Latin America, operating 31 healthcare network facilities and managing 1.4 million healthcare plans, focusing on high-complexity diseases, showcasing its strong integration capabilities in the Spanish-speaking markets.
EsSalud Receives Construction License for Torre Trecca, Signifying Important Milestone in Auna's Public-Private Partnership with the Organization
Construction License Received: Auna S.A. has received a construction license for Torre Trecca, a high-rise outpatient treatment center in Lima, Peru, which will serve over six million EsSalud-insured Peruvians.
Public-Private Partnership: The project is part of a public-private partnership with EsSalud, initiated in 2010, aimed at modernizing healthcare services in the region.
Expected Impact: Once completed, Torre Trecca is projected to accommodate more than three million visits annually, significantly enhancing healthcare access in Lima.
Forward-Looking Statements: Auna's announcement includes forward-looking statements regarding the project's timeline and capacity, emphasizing potential risks and uncertainties that may affect outcomes.
Honeywell Analyst Adopts Bearish Stance; Check Out Tuesday's Top 4 Downgrades
Analyst Downgrades: JP Morgan's Hanzade Kilickiran downgraded D-MARKET Electronic from Overweight to Neutral, lowering the price target from $4.85 to $3.07, with shares closing at $2.31.
Federal Realty Investment Trust: Barclays analyst Richard Hightower downgraded Federal Realty Investment Trust from Overweight to Equal-Weight, reducing the price target from $113 to $106, while shares closed at $96.00.
Auna SA: JP Morgan's Joseph Giordano downgraded Auna SA from Overweight to Neutral, cutting the price target from $13.5 to $6, with shares closing at $5.00.
Honeywell International Inc: B of A Securities analyst Andrew Obin downgraded Honeywell from Buy to Underperform, slashing the price target from $265 to $205, as shares closed at $196.08.
Alphabet Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Tuesday
Analyst Upgrades and Price Target Increases: HC Wainwright & Co. raised the price target for Zymeworks Inc. from $26 to $32 while maintaining a Buy rating. Jefferies also increased the price target for Legence Corp. from $39 to $49 and upgraded the stock from Hold to Buy.
Analyst Downgrades and Price Target Cuts: BTIG cut the price target for LifeMD Inc. from $18 to $10, while JP Morgan reduced Auna SA's target from $13.5 to $6 and downgraded it from Overweight to Neutral.
Mixed Ratings and Price Adjustments: Canaccord Genuity lowered TELA Bio Inc.'s price target from $7 to $4 but kept a Buy rating, whereas B of A Securities cut Honeywell International Inc.'s target from $265 to $205 and downgraded it from Buy to Underperform.
Other Notable Changes: Loop Capital raised Alphabet Inc.'s price target from $260 to $320 and upgraded it from Hold to Buy, while HC Wainwright & Co. increased HIVE Digital Technologies Ltd.'s target from $8 to $10, maintaining a Buy rating.
